(Total Views: 387)
Posted On: 09/27/2025 4:48:48 PM
Post# of 157343
Re: Evil Rabbit #157289
As I understand it, We are conducting an open-label, two-arm, Phase 2 clinical trial combined with SOC therapies... mCRC as the target.
YES open-label trials can be amended which is common such as patient assessments, schedules inclusion/exclusion criteria or for that matter the study's objectives
Both the IRB and Cytodyn must sign off. The patients must sign the amendments.
PD-L1 expressions would also come into play in the Whack-a-mole division.
YES open-label trials can be amended which is common such as patient assessments, schedules inclusion/exclusion criteria or for that matter the study's objectives
Both the IRB and Cytodyn must sign off. The patients must sign the amendments.
PD-L1 expressions would also come into play in the Whack-a-mole division.
(5)
(0)
